NCT02870231View on ClinicalTrials.gov

Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity

PHASE1CompletedINTERVENTIONAL
Enrollment

187

Participants

Timeline

Start Date

August 18, 2016

Primary Completion Date

September 3, 2017

Study Completion Date

September 3, 2017

Conditions
Metabolism and Nutrition DisorderObesity
Interventions
DRUG

NNC9204-0530

Once-daily subcutaneous (s.c., under the skin) administration.

DRUG

liraglutide

Once-daily subcutaneous (s.c., under the skin) administration.

DRUG

placebo

Once-daily subcutaneous (s.c., under the skin) administration

Trial Locations (2)

68502

Novo Nordisk Investigational Site, Lincoln

85283

Novo Nordisk Investigational Site, Tempe

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY